In this matter, synergism of Kras activation and Lkb1 deletion has more pronounced effects in tumor development and progression than combination of Kras activation and loss of p53, p16Ink4a or p19ARF tumor suppressors. The gene discussed is CDKN2A; the disease is neoplasm.